Aktienanalyse zu GT Biopharma Inc (GTBP)GTBPGT Biopharma Inc

GT Biopharma, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of immuno-oncology therapeutic products based on its proprietary Tri-specific Killer Engager (TriKE) natural killer (NK) cell engager platform. Its TriKE platform is designed to harness and enhance the cancer-killing abilities of a patient’s immune system’s natural killer cells. Its product candidate pipeline includes GTB-3550, GTB-3650, GTB-5550, GTB-7550, GTB-6550, GTB-1050, and other product candidates. GTB-3550 is a TriKE comprised of two single-chain variable fragments (scFv) composed of the variable regions of the heavy and light chains of anti-CD16 and anti-CD33 antibodies and a modified form of IL-15. GTB-3650 is a TriKE which targets CD33 on the surface of myeloid leukemias. The Company also has a worldwide license agreement with the University of Minnesota to further develop and commercialize therapies using TriKE technology. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).

GT Biopharma Inc is currently not a strong buy due to its ongoing financial losses and declining stock performance, despite a recent positive trend. The stock closed at $0.30, with a year-to-date decline of 63.28%. The RSI is at 53.044, indicating a neutral momentum, while the forward P/E ratio is 17.331, suggesting potential for future earnings but also a risk given the company’s current losses. The main risk is the significant net loss of $28.4 million reported for FY2025, which raises concerns about profitability and investor confidence.